2023 World Conference on Lung Cancer (Posters)-EP14.04. BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

EP14.04. BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to describe the real-world outcomes of immune checkpoint inhibitor therapy in patients with pleural mesothelioma, with a particular focus on the impact of BAP1 (BRCA-Associated Protein-1) status on therapy response. Pleural mesothelioma is a rare malignancy with limited treatment options, and immune therapy with ipilimumab plus nivolumab has become an approved first-line treatment. BAP1 is a tumor suppressor gene commonly altered in mesothelioma.<br /><br />The researchers identified 87 patients with pleural mesothelioma who had received immunotherapy. The majority of patients (74%) had epithelioid histology, and 35 patients had BAP1 loss, while 22 had retained BAP1 expression. However, BAP1 status was unknown for 30 patients. Immunotherapy was given as first-line, second-line, or third-line treatment, with patients having previously received platinum-based therapy. The most common immunotherapy regimen was ipilimumab plus nivolumab.<br /><br />The median number of cycles of immunotherapy provided was 6, and with a median follow-up of 10.1 months, the progression-free survival was 5.8 months, while the median overall survival was 12.0 months. There was no statistical difference in survival based on histology, BAP1 status, or the number of prior lines of therapy received.<br /><br />The study concluded that BAP1 status did not appear to affect the overall survival of patients receiving immunotherapy for pleural mesothelioma. However, the lack of non-epithelioid patients with BAP1 loss may confound the results, and further research is needed to identify predictive markers for response to immunotherapy in mesothelioma.<br /><br />In summary, this study focuses on the use of immunotherapy and its real-world outcomes in patients with pleural mesothelioma. It specifically examines the impact of BAP1 status on therapy response and finds that overall survival is not affected by BAP1 status. Further research is required to better understand the response to immunotherapy in mesothelioma.

Asset Subtitle

Caleb Smith

Meta Tag

Speaker Caleb Smith

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

immune checkpoint inhibitor therapy

pleural mesothelioma

BAP1 status

therapy response

ipilimumab plus nivolumab

tumor suppressor gene

immunotherapy regimen

progression-free survival

overall survival

predictive markers